Sei Investments Co. Decreases Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Sei Investments Co. lessened its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 42.9% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,070 shares of the company’s stock after selling 24,132 shares during the quarter. Sei Investments Co.’s holdings in Hims & Hers Health were worth $647,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Verition Fund Management LLC lifted its position in shares of Hims & Hers Health by 30.9% during the 4th quarter. Verition Fund Management LLC now owns 798,660 shares of the company’s stock valued at $7,108,000 after acquiring an additional 188,506 shares during the period. Bridgefront Capital LLC boosted its position in Hims & Hers Health by 176.3% during the fourth quarter. Bridgefront Capital LLC now owns 39,622 shares of the company’s stock worth $353,000 after purchasing an additional 25,284 shares in the last quarter. Vanguard Group Inc. boosted its position in Hims & Hers Health by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 14,173,285 shares of the company’s stock worth $126,142,000 after purchasing an additional 46,541 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new stake in Hims & Hers Health in the fourth quarter valued at $155,000. Finally, Los Angeles Capital Management LLC increased its position in shares of Hims & Hers Health by 58.5% in the first quarter. Los Angeles Capital Management LLC now owns 28,206 shares of the company’s stock valued at $436,000 after buying an additional 10,405 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $18.75 on Wednesday. Hims & Hers Health, Inc. has a one year low of $5.65 and a one year high of $25.74. The company has a 50 day moving average price of $16.50 and a 200 day moving average price of $17.31. The firm has a market capitalization of $4.03 billion, a price-to-earnings ratio of -1,877.00 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $315.65 million during the quarter, compared to analysts’ expectations of $302.43 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The company’s revenue for the quarter was up 51.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.03) EPS. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

Insider Activity

In related news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $487,789.12. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Oluyemi Okupe sold 9,868 shares of Hims & Hers Health stock in a transaction on Monday, October 7th. The shares were sold at an average price of $19.96, for a total transaction of $196,965.28. Following the sale, the chief financial officer now owns 195,988 shares of the company’s stock, valued at $3,911,920.48. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the transaction, the chief executive officer now owns 33,502 shares in the company, valued at $487,789.12. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 573,618 shares of company stock valued at $9,329,808. Company insiders own 17.71% of the company’s stock.

Wall Street Analyst Weigh In

HIMS has been the topic of a number of research reports. TD Cowen increased their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Needham & Company LLC began coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective for the company. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Piper Sandler reissued a “neutral” rating and issued a $18.00 price target on shares of Hims & Hers Health in a report on Tuesday, August 6th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.86.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.